Aida Pharmaceuticals Stock Net Income
| AIDA Stock | USD 0.0003 0.00 0.00% |
As of the 10th of February, Aida Pharmaceuticals shows the risk adjusted performance of 0.1074, and Mean Deviation of 1.49. Aida Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
Aida Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Aida Pharmaceuticals' valuation are provided below:Aida Pharmaceuticals does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Aida |
Aida Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Aida Pharmaceuticals' pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Aida Pharmaceuticals.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Aida Pharmaceuticals on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Aida Pharmaceuticals or generate 0.0% return on investment in Aida Pharmaceuticals over 90 days. Aida Pharmaceuticals, Inc., together with its subsidiaries, engages in the formulation, clinical testing, registration, ... More
Aida Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Aida Pharmaceuticals' pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Aida Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | 0.1071 | |||
| Maximum Drawdown | 50.0 |
Aida Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Aida Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Aida Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Aida Pharmaceuticals historical prices to predict the future Aida Pharmaceuticals' volatility.| Risk Adjusted Performance | 0.1074 | |||
| Jensen Alpha | 0.7786 | |||
| Total Risk Alpha | 0.0698 | |||
| Treynor Ratio | (2.13) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Aida Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Aida Pharmaceuticals February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1074 | |||
| Market Risk Adjusted Performance | (2.12) | |||
| Mean Deviation | 1.49 | |||
| Coefficient Of Variation | 812.4 | |||
| Standard Deviation | 6.15 | |||
| Variance | 37.88 | |||
| Information Ratio | 0.1071 | |||
| Jensen Alpha | 0.7786 | |||
| Total Risk Alpha | 0.0698 | |||
| Treynor Ratio | (2.13) | |||
| Maximum Drawdown | 50.0 | |||
| Skewness | 8.12 | |||
| Kurtosis | 66.0 |
Aida Pharmaceuticals Backtested Returns
Aida Pharmaceuticals appears to be out of control, given 3 months investment horizon. Aida Pharmaceuticals secures Sharpe Ratio (or Efficiency) of 0.13, which signifies that the company had a 0.13 % return per unit of standard deviation over the last 3 months. By analyzing Aida Pharmaceuticals' technical indicators, you can evaluate if the expected return of 0.79% is justified by implied risk. Please makes use of Aida Pharmaceuticals' mean deviation of 1.49, and Risk Adjusted Performance of 0.1074 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Aida Pharmaceuticals holds a performance score of 10. The firm shows a Beta (market volatility) of -0.35, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Aida Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Aida Pharmaceuticals is likely to outperform the market. Please check Aida Pharmaceuticals' treynor ratio, rate of daily change, and the relationship between the variance and skewness , to make a quick decision on whether Aida Pharmaceuticals' price patterns will revert.
Auto-correlation | 0.00 |
No correlation between past and present
Aida Pharmaceuticals has no correlation between past and present. Overlapping area represents the amount of predictability between Aida Pharmaceuticals time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Aida Pharmaceuticals price movement. The serial correlation of 0.0 indicates that just 0.0% of current Aida Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Aida Pharmaceuticals reported net income of 2.74 M. This is 99.2% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The net income for all United States stocks is 99.52% higher than that of the company.
Aida Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Aida Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Aida Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Aida Pharmaceuticals by comparing valuation metrics of similar companies.Aida Pharmaceuticals is currently under evaluation in net income category among its peers.
Aida Fundamentals
| Return On Equity | -0.0179 | |||
| Return On Asset | 0.0662 | |||
| Profit Margin | (0.05) % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 8.37 M | |||
| Price To Earning | (0.25) X | |||
| Price To Book | 0.77 X | |||
| Price To Sales | 0.21 X | |||
| Revenue | 29.2 M | |||
| Gross Profit | 14.64 M | |||
| EBITDA | 9.51 M | |||
| Net Income | 2.74 M | |||
| Cash And Equivalents | 8.28 M | |||
| Cash Per Share | 0.31 X | |||
| Debt To Equity | 2.37 % | |||
| Current Ratio | 0.73 X | |||
| Book Value Per Share | 0.34 X | |||
| Cash Flow From Operations | 8.39 M | |||
| Earnings Per Share | (0.08) X | |||
| Number Of Employees | 450 | |||
| Beta | 15.94 | |||
| Market Capitalization | 8.37 M | |||
| Total Asset | 62.73 M | |||
| Retained Earnings | 2.75 M | |||
| Working Capital | (12.09 M) | |||
| Current Asset | 32.28 M | |||
| Current Liabilities | 44.37 M | |||
| Net Asset | 62.73 M |
About Aida Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Aida Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Aida Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Aida Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Aida Pink Sheet
Aida Pharmaceuticals financial ratios help investors to determine whether Aida Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Aida with respect to the benefits of owning Aida Pharmaceuticals security.